KR20230136604A - 개과 항체 불변 영역에서의 돌연변이 - Google Patents

개과 항체 불변 영역에서의 돌연변이 Download PDF

Info

Publication number
KR20230136604A
KR20230136604A KR1020237025434A KR20237025434A KR20230136604A KR 20230136604 A KR20230136604 A KR 20230136604A KR 1020237025434 A KR1020237025434 A KR 1020237025434A KR 20237025434 A KR20237025434 A KR 20237025434A KR 20230136604 A KR20230136604 A KR 20230136604A
Authority
KR
South Korea
Prior art keywords
igg
canine
constant domain
antibody
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237025434A
Other languages
English (en)
Korean (ko)
Inventor
헨리 루이스 캠포스
산드라 앤 마리 라이틀
리사 마리 버거론
Original Assignee
조에티스 서비시즈 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 조에티스 서비시즈 엘엘씨 filed Critical 조에티스 서비시즈 엘엘씨
Publication of KR20230136604A publication Critical patent/KR20230136604A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020237025434A 2021-01-28 2022-01-27 개과 항체 불변 영역에서의 돌연변이 Pending KR20230136604A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163142774P 2021-01-28 2021-01-28
US63/142,774 2021-01-28
PCT/US2022/014146 WO2022165067A2 (en) 2021-01-28 2022-01-27 Mutations in canine antibody constant regions

Publications (1)

Publication Number Publication Date
KR20230136604A true KR20230136604A (ko) 2023-09-26

Family

ID=80786846

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237025434A Pending KR20230136604A (ko) 2021-01-28 2022-01-27 개과 항체 불변 영역에서의 돌연변이

Country Status (15)

Country Link
US (1) US20240059777A1 (https=)
EP (2) EP4284825A2 (https=)
JP (1) JP2024505072A (https=)
KR (1) KR20230136604A (https=)
CN (1) CN116802205A (https=)
AU (1) AU2022214843A1 (https=)
CA (1) CA3207285A1 (https=)
CL (2) CL2023002202A1 (https=)
CO (1) CO2023009994A2 (https=)
EC (1) ECSP23057156A (https=)
IL (1) IL304522A (https=)
MX (1) MX2023008785A (https=)
PE (1) PE20231919A1 (https=)
TW (1) TW202246318A (https=)
WO (1) WO2022165067A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115996949A (zh) * 2020-04-17 2023-04-21 硕腾服务有限责任公司 犬抗体变异体
EP4284825A2 (en) 2021-01-28 2023-12-06 Zoetis Services LLC Mutations in canine antibody constant regions
JP2025529206A (ja) * 2022-09-02 2025-09-04 ゾエティス・サービシーズ・エルエルシー 豚抗体変異体
CN121574951B (zh) * 2026-01-27 2026-04-28 金发科技股份有限公司 一种苹果酸脱氢酶、含有其的工程化库德里亚兹毕赤酵母及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
AU2005285347A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US20200181258A1 (en) * 2016-10-17 2020-06-11 Vetoquinol Sa Modified antibody constant region
US20210388053A1 (en) * 2018-10-18 2021-12-16 Kindred Biosciences, Inc. Fc Variants with Altered Binding to Neonatal Fc Receptor (FCRN) for Veterinary Use
CN113544153B (zh) * 2019-01-03 2024-12-10 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物及使用方法
EP4284825A2 (en) 2021-01-28 2023-12-06 Zoetis Services LLC Mutations in canine antibody constant regions

Also Published As

Publication number Publication date
WO2022165067A2 (en) 2022-08-04
MX2023008785A (es) 2023-12-14
TW202246318A (zh) 2022-12-01
ECSP23057156A (es) 2023-08-31
CA3207285A1 (en) 2022-08-04
CO2023009994A2 (es) 2023-08-09
IL304522A (en) 2023-09-01
EP4512416A2 (en) 2025-02-26
US20240059777A1 (en) 2024-02-22
JP2024505072A (ja) 2024-02-02
CL2024001562A1 (es) 2024-08-23
EP4512416A3 (en) 2025-06-18
AU2022214843A1 (en) 2023-07-20
EP4284825A2 (en) 2023-12-06
PE20231919A1 (es) 2023-11-28
WO2022165067A3 (en) 2022-09-22
CL2023002202A1 (es) 2024-01-12
AU2022214843A9 (en) 2024-05-16
CN116802205A (zh) 2023-09-22

Similar Documents

Publication Publication Date Title
KR20230136604A (ko) 개과 항체 불변 영역에서의 돌연변이
KR20230152062A (ko) 항tslp 항체를 포함하는 의약 조성물
JP2023522030A (ja) ネコ科動物抗体バリアント
TW202233687A (zh) 貓抗體恆定區中之突變
TW202229337A (zh) 犬抗體變異體
RU2739208C2 (ru) Анти-pcsk9 антитело, его антигенсвязывающий фрагмент и их медицинское применение
TWI814094B (zh) 貓抗體變異體
TWI915520B (zh) 含抗tslp抗體的藥物組合物
RU2858900C2 (ru) Варианты кошачьих антител
RU2855157C1 (ru) Мутации в константных областях антител кошек
RU2840969C1 (ru) Варианты кошачьих антител
RU2846726C1 (ru) Варианты собачьих антител
RU2847183C1 (ru) Варианты собачьих антител
EP4543917A2 (en) Canine antibody mutants
JP2025525987A (ja) ウシ亜科動物抗体変異体
HK40097033B (zh) 含抗tslp抗体的药物组合物
HK40097033A (zh) 含抗tslp抗体的药物组合物
KR20250054824A (ko) 돼지 항체 돌연변이체
BR122024006370A2 (pt) Polipeptídeo, seu uso, composição farmacêutica, kit, igg modificada, vetor, célula isolada, molécula de fusão, e seu método de fabricação

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230725

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250116

Comment text: Request for Examination of Application